Clinical Trials for Brain Tumor

Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric and young adult patients (<22 years) with relapsed/refractory intracranial gliomas (including GBM, anaplastic astrocytoma, oligodendroglioma, and radiographically diagnosed DIPG) receive monthly super-selective intra-arterial cerebral infusions of cetuximab (EGFR inhibitor) plus bevacizumab (VEGF-A inhibitor). Aims to enhance intratumoral delivery and assess safety and preliminary efficacy in measurable/evaluable disease with adequate performance status and organ function.

ClinicalTrials.gov ID: NCT05956821

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with non–small cell solid tumors (excluding SCLC/germ cell) and 1–10 brain metastases receive focal radiation via single-fraction SRS or hypofractionated SBRT (up to 3 fractions), selected by the treating team. The study focuses on neurocognitive outcomes, QoL, and intracranial control over 12 months; excludes leptomeningeal disease, recent brain surgery (<14 days), planned concurrent chemo with radiosurgery, and primary high-grade gliomas.

ClinicalTrials.gov ID: NCT03184038

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with 1–3 brain metastases (≤3 cm; intact or post-resection) receive stereotactic radiosurgery planned with advanced DTI and volumetric MRI to spare eloquent white-matter tracts and bilateral hippocampi, aiming to reduce neurocognitive decline versus historical controls. Excludes prior WBRT, leptomeningeal disease, MRI contraindications, and certain histologies (germ cell, small cell, primary CNS lymphoma).

ClinicalTrials.gov ID: NCT04343157

Adopting a Functional Precision Medicine Approach For Individualized Pediatric Cancer Treatments

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Children, adolescents, and young adults (≤21 years) with relapsed or refractory solid or hematologic malignancies and accessible tumor tissue undergo ex vivo drug sensitivity testing integrated with genomic profiling to guide individualized therapy selection. Treating physicians may use matched, typically approved monotherapies or combinations based on predicted sensitivity; outcomes are compared with contemporaneous patients receiving non–FPM standard-of-care therapy.

ClinicalTrials.gov ID: NCT05857969

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with solid tumor brain metastases (ECOG 0–1, no prior WBRT, no leptomeningeal disease) receive upfront pulsed reduced dose-rate whole-brain radiation therapy (30 Gy/10 fx) plus memantine to assess feasibility and explore neurocognitive outcomes versus historical WBRT. Prior SRS or resection and prior systemic therapy are allowed with washouts; excludes primary CNS/hematologic malignancies and large (>5 cm) unresected lesions.

ClinicalTrials.gov ID: NCT05045950

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Children and young adults (6–21) with recurrent primary brain tumors lacking curative options or relapsed/refractory solid tumors after ≥2 prior lines receive standard chemotherapy plus dapagliflozin, an SGLT2 inhibitor (metabolic modulation via reduced glucose/insulin and ketone shift) to assess safety/feasibility and preliminary activity. Regimens include carmustine+dapagliflozin for brain tumors and topotecan/cyclophosphamide+dapagliflozin for solid tumors, with age-based dapagliflozin dosing and close metabolic/renal monitoring due to risks such as euglycemic ketoacidosis and infections.

ClinicalTrials.gov ID: NCT05521984

Pilot Trial of Spectroscopic MRI-guided, Dose-Escalated Proton Radiation Therapy and Bevacizumab for Recurrent Glioblastoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent glioblastoma or gliosarcoma after prior standard brain RT (≤63 Gy), ECOG 0–2, single measurable lesion ≤6 cm, receive spectroscopic MRI-guided focal proton re-irradiation (IMPT, 35 Gy/10 fx or 40 Gy/10 fx with SIB) combined with bevacizumab (anti–VEGF-A monoclonal antibody) started before RT. Excludes multifocal disease, prior re-irradiation or bevacizumab, and lesions in regions prone to sMRI artifact.

ClinicalTrials.gov ID: NCT05284643

A Randomized Trial Evaluating GLIADEL Compared to Stereotactic Radiosurgery in Subjects With Metastatic Brain Disease

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with 1–4 resectable brain metastases (≤4 cm) from solid tumors (RPA I–III, KPS ≥60) are randomized intraoperatively to local chemotherapy with GLIADEL carmustine (BCNU) wafers placed in the resection cavity versus standard postoperative stereotactic radiosurgery to the cavity; remaining lesions (up to three) receive SRS. GLIADEL delivers high local concentrations of the alkylating agent BCNU (DNA crosslinker), and the trial compares local control at 12 months, with neurocognitive and genomic correlatives.

ClinicalTrials.gov ID: NCT04222062

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with 1–4 resectable brain metastases (≥1 lesion 20–50 mm) from solid tumors (excluding SCLC, lymphoma, germ cell), KPS ≥70, receive neoadjuvant stereotactic radiosurgery to the target lesion followed by gross total resection within 2 weeks; remaining lesions, if any, are treated with SRS. Excludes prior WBRT, brainstem lesions, leptomeningeal disease, and inability to meet optic apparatus dose constraints.

ClinicalTrials.gov ID: NCT01891318

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with melanoma and at least one measurable, untreated brain metastasis (0.5–3 cm), ECOG 0–1, and no steroid-requiring neurologic symptoms receive fixed-dose nivolumab (PD-1 inhibitor) plus relatlimab (LAG-3 inhibitor) IV every 28 days. Prior limited SRT/excision allowed if non-irradiated measurable disease remains; excludes leptomeningeal disease, lesions >3 cm, prior metastatic PD-1 therapy, and significant autoimmune/infectious comorbidities.

ClinicalTrials.gov ID: NCT05704647